Post Session: Sensex ends 40 pts higher on buying in FMCG, pharma stocks 15/09/2016 16:09

Post Session: Sensex ends 40 pts higher on buying in FMCG, pharma stocks
15/09/2016 16:09

NIFTY Fut               : SELL ZONE
BANKNIFTY FUT : SELL ZONE


 Click Here  & Register To Get 2 days Trial Tips
Free Intraday Tips : Join Our Whatsapp No : 9841986753
The Indian equities ended tad higher for the second straight session on Thursday, led by gains in FMCG and pharma stocks, amid rising expectations of an interest rate cut by the RBI in October after consumer inflation dipped to a five-month low in August. However, weakness across many markets in Asia ahead of key central bank meetings in Japan and the US next week restricted upward move.

The 30-share BSE SENSEX closed at 28412.89, up by 40.66 points or by 0.14 per cent, and the NSE Nifty ended at 8742.55, up by 15.95 points or by 0.18 per cent.

Even as the US Fed is pondering over an interest rate lift-off, analysts are divided over whether the Bank of Japan will dish out further monetary stimulus next week but could cut interest rates deeper into the negative territory.

On the global front, Asian stocks ended mixed as cautioned ruled sentiment ahead of upcoming central bank meetings next week. Shanghai Composite was closed today, Hang Seng ended with modest losses while Japan’s Nikkei 225 sank over 1 per cent as a stronger yen curbed the lure for exporter stocks.

DISCLAIMER

The suggestions made herein are for information purposes and are not recommendations to any person to buy or sell any securities. The information is derived from various sources that are deemed to be reliable but its accuracy and completeness are not guaranteed.Our blog does not accept any liability for the use of this column. Readers of this column who buy or sell securities based on the information in this column are solely responsible for their actions. And we won't be liable or responsible for any legal or financial losses made by anyone .Any surfing and reading of the information available in this blog is the acceptance of this disclaimer.